Solid Biosciences (NASDAQ:SLDB) Shares Gap Up After Earnings Beat

Solid Biosciences Inc. (NASDAQ:SLDB) shares gapped up before the market opened on Friday following a better than expected earnings announcement. The stock had previously closed at $7.12, but opened at $7.46. Solid Biosciences shares last traded at $7.2340, with a volume of 316,148 shares trading hands.

The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.01.

More Solid Biosciences News

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Guggenheim started coverage with a Buy and a $26 price target (implies ~272% upside from recent levels), giving formal street-level momentum and a large upside case for the stock. Guggenheim starts coverage (Benzinga)
• Positive Sentiment: Needham reaffirmed Buy with a $19 price target, signaling continued analyst conviction in the company’s clinical progress and longer-term value. Needham reaffirms buy (Benzinga)
• Positive Sentiment: Chardan reaffirmed its Buy rating and $15 target, adding to the cluster of upgrade/reaffirmation headlines that can attract investor attention and trading demand. Chardan reaffirms buy (TickerReport)
• Positive Sentiment: Solid reported positive interim Phase 1/2 INSPIRE data for SGT-003 at the 2026 MDA meeting; the readout highlights generally favorable tolerability in 41 dosed participants—this is the primary fundamental catalyst supporting higher valuations. SGT-003 interim data (GlobeNewswire)
• Neutral Sentiment: The company issued its Q4 and full-year 2025 results and broader business updates; the release contains operational context and program timelines that investors will parse for runway and development plans. Q4 & full-year 2025 results (FinanzNachrichten)
• Negative Sentiment: SLDB missed Q4 EPS expectations (reported -$0.53 vs. consensus -$0.48), underlining ongoing losses and near-term profitability risk that likely capped the stock’s upside today. Earnings press release (Quartr)

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price target on shares of Solid Biosciences in a report on Friday. Chardan Capital reissued a “buy” rating and set a $15.00 price objective on shares of Solid Biosciences in a research note on Friday. Wedbush restated an “outperform” rating and issued a $14.00 target price on shares of Solid Biosciences in a report on Wednesday, March 11th. Citigroup reaffirmed a “market outperform” rating on shares of Solid Biosciences in a research report on Wednesday, December 17th. Finally, Guggenheim began coverage on Solid Biosciences in a report on Friday. They set a “buy” rating and a $26.00 target price for the company. Eleven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Insider Activity at Solid Biosciences

In related news, Director Ilan Ganot sold 7,205 shares of the firm’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $6.44, for a total value of $46,400.20. Following the transaction, the director directly owned 25,271 shares in the company, valued at approximately $162,745.24. This trade represents a 22.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO David T. Howton sold 7,469 shares of the business’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $5.82, for a total transaction of $43,469.58. Following the transaction, the chief operating officer directly owned 105,077 shares of the company’s stock, valued at approximately $611,548.14. This represents a 6.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 597,672 shares of company stock worth $3,816,546 in the last 90 days. Insiders own 1.90% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Vestal Point Capital LP grew its position in Solid Biosciences by 95.5% in the 4th quarter. Vestal Point Capital LP now owns 5,815,000 shares of the company’s stock worth $32,797,000 after purchasing an additional 2,840,000 shares during the last quarter. Armistice Capital LLC grew its position in Solid Biosciences by 179.1% during the fourth quarter. Armistice Capital LLC now owns 2,612,000 shares of the company’s stock worth $14,732,000 after buying an additional 1,676,000 shares in the last quarter. Nantahala Capital Management LLC grew its position in Solid Biosciences by 505.4% during the second quarter. Nantahala Capital Management LLC now owns 1,703,336 shares of the company’s stock worth $8,295,000 after buying an additional 1,421,968 shares in the last quarter. Monashee Investment Management LLC bought a new position in Solid Biosciences during the fourth quarter valued at about $7,613,000. Finally, Geode Capital Management LLC raised its holdings in Solid Biosciences by 184.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,510,153 shares of the company’s stock valued at $7,356,000 after acquiring an additional 979,294 shares in the last quarter. 81.46% of the stock is currently owned by institutional investors and hedge funds.

Solid Biosciences Stock Performance

The business’s 50 day moving average price is $6.43 and its 200-day moving average price is $5.80. The company has a market cap of $547.71 million, a price-to-earnings ratio of -3.48 and a beta of 2.65.

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.